Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Published Online: 2021-08-?
Journal: The Lancet Diabetes & Endocrinology•Publisher: Elsevier BV
Authors: Aaron S Mansfield•Bhumsuk Keam•Chia-Chi Lin•Christina S Baik•Christopher D Turner•Corinne Clifford•Daniel W Bowles•Debashis Sarker•Douglas Adkins•Elena Garralda•Gilberto Lopes•Giuseppe Curigliano•Hui Zhang•Ignacio Matos•Justin F Gainor•Lori J Wirth•Marcia S Brose•Martin Schuler•Matthew H Taylor•Mimi I Hu•Sophie Leboulleux•Stephen G Miller•Viola W Zhu•Vivek Subbiah•Yann Godbert
